Written question asked by Daniel Zeichner (Labour) on Thursday, 30 June 2016, in the House of Commons. It was due for an answer on Monday, 4 July 2016. It was answered by George Freeman (Conservative) on Friday, 8 July 2016 on behalf of the Department for Business, Innovation and Skills.
Medical Treatments
- Question
-
To ask the Secretary of State for Business, Innovation and Skills, what engagement his Department has had with the Accelerated Access Review (AAR); and whether the AAR plans to investigate expediting the delivery of new drugs and devices to tackle MRSA and antimicrobial resistance.
- Answer
-
The Accelerated Access Review team is a joint unit between the Department of Health and the Department for Business, Innovation and Skills. The Accelerated Access Review is intended to reform the landscape for the assessment, adoption and reimbursement of innovative drugs, devices and other treatments across all therapeutic areas.
Secondary information
- Type
- Written question
- Reference
- 41572
- Session
- 2016-17
- Subjects
- NHS Medical treatments MRSA Technology Antimicrobials
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2019-08-21 12:36:24 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/41572
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/41572
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2016-17/41572